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Trends in Periodontal Regeneration
Therapy: Potential Therapeutic Strategy
of Extracellular Matrix Administration
for Periodontal Ligament Regeneration
Masahiro Saito
Abstract Current strategy for the treatment of periodontal disease is to application
of stem cells or functional molecules that can reorganize tissue integrity, cellular
activities and extracellular matrix framework to recover peridontal tissue function.
The approach to be regeneration of periodontal ligament (PDL) that is a tooth
supporting connective tissue has made a progress for consideration of strategies in
regeneration therapy of periodontal tissue damaged by periodontitis. To realize the
achieving functional PDL regeneration, the application of stem cells and functional
molecules which are essential for PDL regeneration/developmentmust be developed.
The identification of stem cells/progenitors and functional molecules that contribute
PDL regeneration will substantial contribution for realization of the regeneration
therapy as a novel treatment of connective tissue disease. This review describes
current strategy of functional PDL regeneration based on development, stem cell
biology and tissue engineering after pathological degradation by periodontitis. The
present status of the hurdles to this technology are also described and discussed.
Keyword Extracellular matrix • Marfan syndrome • Microfibril • Periodontal
ligament • Regeneration therapy
14.1 Introduction
The current advances in future regenerative therapies have been influenced by
many previous studies of embryonic development, stem cell biology, and tissue
engineering technologies [1, 2]. To restore the partial loss of organ functions and to
repair damaged tissues, attractive concepts that have emerged in regenerative
therapy is stem cell transplantation into various tissues and organs [3] and cytokine
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therapy, which has the potential to induce the activation and differentiation of tissue
stem/progenitor cells [4]. PDL stem cells and the cytokine network that involved
PDL formation and dental follicle cell growth and differentiation, have been well
characterized at the molecular level [5–7]. Based on these results, regeneration of
periodontal tissues is being made clinically possible by the transplantation of
mesenchymal stem cells which can differentiate into PDL cells, cementoblasts
and osteoblasts, or through the local application of cytokines to stimulate the
proliferation and differentiation of these stem cells [8–10]. Although these thera-
pies are effective and contribute to periodontal tissue repair, these interventions will
likely be improved by an enhanced understanding of the development of periodon-
tal tissues, particularly those involved in the formation of PDL, cementum and
alveolar bone.
Fibrillin-1 comprises one of the major insoluble extracellular matrix components
in connective tissue microfibrils and provides limited elasticity to tissues through
microfibril formation [11]. Various mouse models revealed that Marfan syndrome
(MFS) is a severe, systemic disorder of connective tissue formation and can lead to
aortic aneurysms, ocular lens dislocation, emphysema, bone overgrowth and severe
periodontal disease [12]. MFS have been established via gene targeting or missense
mutations, with germline mutations in fibrillin-1 leading to progressive connective
tissue destruction due to fibrillin-1 fragmentation in association with an insuffi-
ciency of fibrillin-1 microfibril formation [13]. Hence, it is largely accepted that
MFS is caused by insufficient fibrillin-1 microfibril formation in various connective
tissues [14]. Fibrillin-1 has been shown to contribute to the formation and mainte-
nance of periodontal ligament. An abnormal PDL structure in association with the
progressive destruction of microfibrils has been observed in a Marfan’s syndrome
mouse model. These findings have strongly suggested that microfibril formation
through fibrillin-1 assembly provides a novel therapeutic strategy for the treatment
of periodontal disease.
We here review the present status of the periodontal tissue regeneration
technologies that focus on the molecular mechanisms underlying development,
regeneration and tissue engineering of periodontal tissue, and also discuss the poten-
tial of ECM administration therapy through the promotion of microfibril assembly as
a novel therapeutic strategy for the essential functional recovery of periodontal tissue.
14.2 Periodontal Ligament Development
The PDL has essential roles in tooth support, homeostasis, and repair, and is
involved in the regulation of periodontal cellular activities such as cell prolifera-
tion, apoptosis, the secretion of extracellular matrices, resorption and repair of the
root cementum, and remodeling of the alveolar bone [15]. To develop future
methods to regenerate damaged PDL, it will be important to understand the
molecular basis of PDL development and also how the destruction of the PDL
occurs during periodontal disease.
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14.2.1 Developmental Process of Dental Follicle
The PDL is derived from the dental follicle (DF), which is located within the outer
mesenchymal cells of the tooth germ and can generate a range of periodontal
tissues including the PDL, cementum and alveolar bone 21. The DF is formed
during the cap stage of tooth germ development by an ectomesenchymal progen-
itor cell population originating from the cranial neural crest cells [16]. Given the
critical role that the progenitor cell population in the DF appears to play in the
development of periodontal tissue, the developmental processes in this tissue are
of considerable interest in terms of further understanding the biology of these cells
[17]. The differentiation of the DF proceeds as follows: (1) during the tooth root
forming stage, the Hertwig’s epithelial root sheath (HERS) comprising the inner-
and outer-dental epithelia that initiate tooth root dentin formation is fragmented
into the Mallasez epithelium resting on the tooth root surface; (2) the DF migrates
to the surface of the tooth root and differentiates into cementoblasts to form the
cementum matrix [18, 19]; (3) at almost the same time, the DF differentiates into
the PDL on the cementoblasts in order to insert collagen fibers, known as
Sharpey’s fibers, into the cementum matrix. Fiber insertion also takes place
along the alveolar bone; and (4) both bone- and PDL-derived fibers finally
coalesce in the PDL to form the intermediate plexus, which resembles tendinous
tissue [20].
14.2.2 Tendon/Ligament Related Molecules Involved
in DF Development
Although the molecular mechanisms of DF development and differentiation remain
to be determined, previous gene expression studies of mouse molar root develop-
ment have suggested that some growth factors, including bone morphogenetic
protein 4, growth and differentiation factors (GDFs)-5, 6, and 7 [21, 22], epidermal
growth factors [23], Shh [24], and insulin-like growth factor-1 [25], are involved in
the growth or differentiation of the DF. Transcriptional factors such as Scleraxis,
Gli, Msx1, Msx2 and Runx2 have also been shown to be involved in the differen-
tiation of the DF into cementoblasts and in the mineralization of cementum
[20, 26]. Among these factors, GDFs and scleraxis are the most well characterized
that are involved in tendon/ligament morphogenesis, suggesting that PDL devel-
opment shares similar molecular mechanisms to those of tendon/ligament morpho-
genesis [20, 27]. These observations strongly suggest that the tendon/ligament
related cytokines regulate induction of extracellular matrix (ECM) component to
the formation of the tendinous structure of the PDL. The mechanisms involving
fibrous ECM network formation may also have a role in formation of the DF
development.
14 Trends in Periodontal Regeneration Therapy: Potential Therapeutic Strategy. . . 171
14.3 Microfibril is Essential for PDL Maintenance
and Formation
The ECM is a biologically active molecule composed of a complex mixture of
macromolecules that, in addition to serving a structural function, profoundly affect
the tendon/ligament formation [28]. Global gene expression analysis of PDL
forming stage have revealed that ECM components including type I collagen,
type III collagen, lumican, decorin, periostin, f-spondin, tenascin-N, fibrillin-1
and PLAP1/aspirin are highly expressed during PDL formation [29, 30].
14.3.1 Fibrillin-1 Regulate PDL Formation
and Maintenance
Among the ECM formations in the PDL, fibrillin-1, a major component of the
microfibrils that regulate tissue integrity and elasticity, has been shown to contrib-
ute to the formation and maintenance of PDL [31]. Various mouse models of
Marfan’s syndrome (MFS) have been established via gene targeting or missense
mutations, with germline mutations in fibrillin-1 leading to progressive connective
tissue destruction due to fibrillin-1 fragmentation in association with an insuffi-
ciency of fibrillin-1 microfibril formation [32–35]. Hence, it is largely accepted that
MFS is caused by insufficient fibrillin-1 microfibril formation in various connective
tissues. MFS have been shown to increase the susceptibility to severe periodontal
disease due to a dysfunction of the PDL through a microfibril insufficiency,
suggesting that fibrillin-1 microfibril formation plays a central role in PDL forma-
tion [36]. MFS patient have been shown that periodontal disease is progressed
severely compared with non MFS patient [37]. These findings have strongly
suggested that microfibril formation through fibrillin-1 assembly plays an important
role in PDL formation and function. However, the molecular mechanisms of
fibrillin-1 microfibril assembly remain unclear as the microfibril-associated mole-
cule that regulates or stabilizes fibrillin-1 microfibril formation has not yet been
identified.
14.3.2 Strategy of MFS Treatment
MFS is a severe, systemic disorder of connective tissue formation and can lead to
aortic aneurysms, ocular lens dislocation, emphysema, bone overgrowth and severe
periodontal disease. A variety of MFS therapies have been developed, including
surgical therapy for aortic root aneurysms that are life-threatening, traditional
medical therapies such as β-adrenergic receptor blockade for slow aortic growth
and to decrease the risk of aortic dissection [14]. It has been demonstrated also that
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systemic antagonism of Transforming Growth Factor-type beta (TGF-β) signaling
through the administration of a TGF-β neutralizing antibody or losartan, an angio-
tensin II type 1 receptor blocker, has been shown to have a beneficial effect on
alveolar septation and muscle hypoplasia in MFS [33, 38] However, another
potential therapeutic strategy which remains to be investigated is the reconstruction
of the microfibril in connective tissues through the expression or administration of a
microfibril-associated molecule that regulates or stabilizes fibrillin-1 microfibril
formation. To investigate this concept, it will be necessary to identify molecular
mechanisms of microfibril formation and an appropriate fibrillin-1 microfibril
associated molecule (Fig. 14.1).
b
Fig. 14.1 Schematic representation of the MFS and ECM administration therapy as a novel
therapeutic strategy for the treatment of MFS. Left panel: Fibrillin-1 comprises insoluble
extracellular matrix components in connective tissue microfibrils and provides limited elasticity
to tissues through fibrillin-1 microfibril formation. Missense mutations of fibrillin-1 leading to
progressive connective tissue destruction due to fibrillin-1 fragmentation in association with an
insufficiency of fibrillin-1 microfibril formation. ADAMTSL6β is essential for fibrillin-1 micro-
fibril formation and suggest a novel therapeutic approach to the treatment of MFS through the
promotion of ADAMTSL6β-mediated fibrillin-1 microfibril assembly. Right Panel: A variety of
MFS therapies have been developed, including surgical therapy for aortic root aneurysms that are
life-threatening, traditional medical therapies such as β-adrenergic receptor blockade for slow
aortic growth and to decrease the risk of aortic dissection, and novel approaches based on new
insights such as the deregulation of TGF-β activation. ECM reinforcement therapy which induces
restoration of properly formed microfibrils by ADAMTSL6β is essential not only for improvement
of the predominant symptoms of MFS, but also for the suppression of excessive TGF-β signaling
induced by microfibril disassembly. Image from published paper [39]
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14.4 Novel Approaches to Periodontal Tissue Regeneration
Using ECM Administration Therapy
ECM components organized in the PDL not only reflect the functional requirements
of this matrix such as mechanical stress and storage of signaling molecules, but also
regulate the tissue framework during development and regeneration [30]. In addi-
tion, a new therapeutic concept has proposed that a fibrillin-1 microfibril insuffi-
ciency can be corrected by the administration of ECM components.
14.4.1 ADAMTSL6β Serves as a Novel Molecules that
Regulate Microfibril Assembly
A disintegrin-like metalloprotease domain with thrombospondin type I motifs
(ADAMTS)-like, ADAMTSL, is a subgroup of the ADAMTS superfamily that
shares particular protein domains with the ADAMTS protease, including
thrombospondin type I repeats, a cysteine-rich domain, and an ADAMTS spacer,
but lacks the catalytic and disintegrin-like domains [40]. A recent study has
demonstrated that ADAMTSL2 mutations cause geleophysic dysplasia, an autoso-
mal recessive disorder similar to MFS, through the dysregulation of TGF-β signal-
ing [41]. A homozygous mutation in ADAMTSL4 also causes autosomal-recessive
isolated ectopia lentis, another disease similar to MFS which is characterized by the
subluxation of the lens as a result of disruption of the zonular fibers [42]. The novel
ADAMTSL family molecules ADAMTSL6α and 6β were recently identified by in
silico screening for novel ECM proteins produced from a mouse full-length cDNA
database (FANTOM). These proteins are localized in connective tissues, including
the skin, aorta and perichondrocytes. Among ADAMTSL6, ADAMTSL6β has
shown to associated with fibrillin-1 microfibrils through its direct interaction with
the N-terminal region of fibrillin-1 and promotes fibrillin-1 matrix assembly in vitro
and in vivo [43]. These findings suggest a potential clinical application of
ADAMTSL6β as a novel MFS therapy by promoting fibrillin-1 microfibril assem-
bly and regulating TGF-β activation.
It is also suggested that the administration of fibrillin-1 microfibrils provides a
novel therapeutic strategy for the treatment of periodontal disease.
14.4.2 ADAMTSL6β Regulates Microfibril Assembly
To investigate whether ADAMTSL6β plays a critical role in microfibril assembly in
connective tissues, we generated ADAMTSL6β transgenic mice (TSL6β-TG mice)
in which the transgene is expressed in the whole body. Since ADAMTSL6β has
shown to be expressed in the aorta and skin, we investigated microfibril assembly of
these tissues in the TSL6β-TG mice. Immunohistochemical analysis revealed that
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ADAMTSL6β positive microfibril assembly was barely detectable in WT mice but
strongly induced in the aorta of TSL6β-TG mice (Fig. 14.2). Histological analysis
revealed that microfibrils are clearly increased in the aorta and that microfibril
assembly is also induced in the skin and PDL of TSL6βTG mice. This confirmed
that ADAMTSL6β induces fibrillin-1 microfibril assembly in connective tissue
such as the aorta, skin and PDL.
14.4.3 ADAMTSL6β Involved in PDL Formation and Repair
To investigate whether ADAMSL6β contributes to PDL formation, we first exam-
ined its expression patterns during PDL forming stage of DF in the developing tooth
germ. In situ hybridization analysis revealed that ADAMSL6β was strongly
expressed in the PDL forming stage of the DF however ADAMSL6β expression
was significantly downregulated in the adult PDL. Immunohistochemical analysis
further revealed that ADAMSL6β is detectable in assembled microfibril-like struc-
tures during the PDL forming stage of the DF, and in organized microfibrils in the
adult PDL. Because developmental processes involve similar mechanisms to
wound healing, we next determined whether ADAMSL6β is involved in PDL
microfibril assembly during wound healing using a tooth replantation model.
Histochemical analysis revealed that both fibrillin-1 and ADAMSL6β expressions
were found to be clearly induced during wound healing of PDL, but to decrease
again after healing. These findings suggested that ADAMSL6β was involved in
microfibril formation during PDL formation/regeneration.
Fig. 14.2 Immunohistochemical analysis of TSL6β-TG mice. Cryosections were prepared from
the aortas (left), skin (middle) or PDL (right) of wild type (upper panel) or TSL6β TG (lower
panel) littermates and subjected to double immunostaining with antibodies against ADAMTSL6β
(red) and fibrillin-1 (green). ADAMTSL6β and fibrillin-1-positive microfibrils (green yellow) was
markedly increased in the aorta and skin of TSL6β TGmice compared withWTmice. Bar¼ 50 μm
Image from published paper [39]
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Since oxytalan fiber, a principal elastic fiber system of PDL is composed of
fibrillin-1 microfibrils and does not contain significant amounts of elastin [44, 45],
this composition suggests that PDL will have an increased susceptibility to break-
down in MFS compared with other elastic tissues composed of both elastin and
fibrillin-1 [46]. We demonstrated that ADAMSL6β is highly expressed in DF
during PDL forming stage. In addition, intense expression of ADAMTSL6β can
be seen in wound healing process of PDL, indicating that this protein involved in
recovery of damaged PDL. Using an animal model of MFS, we demonstrate that
local administration of ADAMSL6β can rescue fibrillin-1 microfibril formation
through the promotion of fibrillin-1 microfibril assembly in PDL (Fig. 14.3). These
results strongly indicate that ADAMTSL6β is essential for fibrillin-1 microfibril
formation and suggest a novel therapeutic approach to the treatment of periodontal
disease with MFS.
14.5 Conclusion
Regenerative therapy for the periodontal disease has been attempted to use of
patient’s own cells to recover periodontal defect. Predictable treatment for partial






Fig. 14.3 ADAMSL6β improves microfibril disorder in PDL from an MFS model. (a) Schematic
representation of the local administration of recombinant ADAMSL6β into a PDL injury model
(b) After injury of PDL by dislocation, collagen gel-containing recombinant ADAMSL6β was
then injected into the injured PDL (left). Immunohistochemical analysis showed an improvement
in fibrillin-1 microfibril assembly (arrowheads) induced by the injection of recombinant
ADAMSL6β. WO: Without treatment of ADAMSL6β. Image from published paper [17]
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plantation has been established, thus regenerative medicine for PDL has made the
most useful study model and is feasible clinical study for the planning of stem cell-
and cytokine- therapies [47]. Although partial regeneration of the periodontal tissue
has been established, novel treatment must be developed corresponding to regen-
erate large defect destroyed by severe periodontal disease. To approach this criti-
cism, it is essential to understand the molecular mechanisms of PDL development
to identify the appropriate functional molecules of inducing differentiation of stem
cells into periodontal lineage cells for successful reconstruction of periodontal
tissue [17, 48, 49].
In this review, we proposed that fibrillin-1 associated protein such as
ADAMTSL6β, which induces microfibril assembly, should be considered as an
ECM administration agent for the treatment of periodontal disease and improve-
ment of connective tissue disorders such as MFS. The exogenous application of
recombinant ADAMTSL6β improves fibrillin-1 microfibril assembly, indicating
the reinforcement of fibrillin-1 microfibrils by ADAMTSL6β may represent a new
treatment for periodontal disease which is accessible from oral cavity in MFS
patients. Since elastolysis occurs continuously in aortic aneurysms arising in
MFS cases, the chronic administration of ADAMTSL6β may be required for the
stabilization of microfibrils to prevent progressive tissue destruction. It will also be
necessary to develop methodologies for the systemic administration of
ADAMTSL6β to induce fibrillin-1 microfibril assembly in connective tissue for
the treatment of life-threatening conditions such as an aortic aneurysm (Fig. 14.4).
Fig. 14.4 ECM administration therapy as a novel therapeutic strategy of MFS syndrome. ECM
administration therapy using ADAMTSL6β which induces microfibril assembly, should be con-
sidered in the development of future mechanism-based therapeutics for the improvement of
connective tissue disorders such as MFS. Image from published paper [17]
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Hence, an ECM administration therapy involving ADAMTSL6β has the capacity to
facilitate drug discovery for treating periodontal diseases, and MFS-associated
disorders.
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